# Long-term Safety of Eplontersen Treated aTTR Patients and in Liver Transplant and Severely Hepatic Impaired Subpopulations

> **NCT07654855** · — · RECRUITING · sponsor: **AstraZeneca** · enrollment: 320 (estimated)

## Conditions studied

- Transthyretin Amyloidosis
- Transthyretin Amyloidosis With Cardiomyopathy
- Transthyretin Amyloidosis With Polyneuropathy

## Interventions

- **OTHER:** None ( observational study )

## Key facts

- **NCT ID:** NCT07654855
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2032-01-29
- **Final completion:** 2032-01-29
- **Target enrollment:** 320 (ESTIMATED)
- **Last updated:** 2026-09-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07654855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07654855, "Long-term Safety of Eplontersen Treated aTTR Patients and in Liver Transplant and Severely Hepatic Impaired Subpopulations". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07654855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*